Comparative Pharmacology
Head-to-head clinical analysis: ABITREXATE versus METHOTREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABITREXATE versus METHOTREXATE.
ABITREXATE vs METHOTREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient, is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, inhibiting DNA synthesis, repair, and cellular replication. It also has immunosuppressive and anti-inflammatory effects via modulation of adenosine and cytokine pathways.
Folate antimetabolite; inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate (DHF) to tetrahydrofolate (THF), thereby inhibiting DNA synthesis, repair, and cellular replication. Also inhibits thymidylate synthetase and purine synthesis.
7.5 mg orally once weekly; alternatively, 7.5 mg subcutaneously once weekly. Dose may be increased by 2.5 mg every 1-2 weeks up to 20 mg once weekly based on response and tolerability.
7.5-25 mg orally once weekly; alternatively, 10-25 mg intramuscularly, intravenously, or subcutaneously once weekly.
None Documented
None Documented
Clinical Note
moderateMethotrexate + Digoxin
"Methotrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethotrexate + Digitoxin
"Methotrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethotrexate + Deslanoside
"Methotrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethotrexate + Acetyldigitoxin
"Methotrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 6-12 hours (mean 7.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal half-life: 3-10 hours (low dose) to 8-15 hours (high dose); clinical context: prolonged to 24-48 hours in renal impairment, third-space effusions, or polyglutamation. Delayed elimination due to enterohepatic recirculation.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for <10%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <10% as metabolites (7-hydroxymethotrexate).
Category C
Category D/X
Antimetabolite
Antimetabolite